Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
- Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes onlyRR 0.9 [0.74, 1.11]3 studies · 4070 participantsModerate